Ferulic acid

Identification

Name
Ferulic acid
Accession Number
DB07767
Type
Small Molecule
Groups
Experimental
Description
Not Available
Structure
Thumb
Synonyms
Not Available
External IDs
NSC-2821 / NSC-51986 / NSC-674320
Categories
UNII
AVM951ZWST
CAS number
1135-24-6
Weight
Average: 194.184
Monoisotopic: 194.057908808
Chemical Formula
C10H10O4
InChI Key
KSEBMYQBYZTDHS-HWKANZROSA-N
InChI
InChI=1S/C10H10O4/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+
IUPAC Name
(2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid
SMILES
COC1=CC(\C=C\C(O)=O)=CC=C1O

Pharmacology

Indication
Not Available
Structured Indications
Not Available
Pharmacodynamics
Not Available
Mechanism of action
TargetActionsOrganism
UEndo-1,4-beta-xylanase YNot AvailableClostridium thermocellum
UEndo-1,4-beta-xylanase ZNot AvailableClostridium thermocellum (strain ATCC 27405 / DSM 1237)
UEst1eNot AvailableButyrivibrio proteoclasticus
UO-methyltransferaseNot AvailableSynechocystis sp. (strain PCC 6803 / Kazusa)
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may increase the anticoagulant activities of Ferulic acid.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with 5-androstenedione.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Ferulic acid.Experimental
AbciximabFerulic acid may increase the anticoagulant activities of Abciximab.Approved
AcebutololAcebutolol may increase the hypotensive activities of Ferulic acid.Approved, Investigational
AceclofenacAceclofenac may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolFerulic acid may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
Acetylsalicylic acidAcetylsalicylic acid may increase the anticoagulant activities of Ferulic acid.Approved, Vet Approved
AclarubicinFerulic acid may decrease the excretion rate of Aclarubicin which could result in a higher serum level.Investigational
AdapaleneAdapalene may increase the anticoagulant activities of Ferulic acid.Approved
AlclofenacAlclofenac may increase the anticoagulant activities of Ferulic acid.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Alclometasone.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Aldosterone.Experimental, Investigational
AldoxorubicinFerulic acid may decrease the excretion rate of Aldoxorubicin which could result in a higher serum level.Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Alendronic acid.Approved
AlfuzosinAlfuzosin may increase the hypotensive activities of Ferulic acid.Approved, Investigational
AliskirenFerulic acid may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AllylestrenolThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Allylestrenol.Approved
AlminoprofenAlminoprofen may increase the anticoagulant activities of Ferulic acid.Experimental
AloxiprinAloxiprin may increase the anticoagulant activities of Ferulic acid.Experimental
AlprenololAlprenolol may increase the hypotensive activities of Ferulic acid.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Ferulic acid.Approved, Investigational
AlteplaseAlteplase may increase the anticoagulant activities of Ferulic acid.Approved
AltrenogestThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Altrenogest.Vet Approved
AmbrisentanFerulic acid may increase the hypotensive activities of Ambrisentan.Approved, Investigational
AmcinonideThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Amcinonide.Approved
AmifostineFerulic acid may increase the hypotensive activities of Amifostine.Approved, Investigational
AmikacinFerulic acid may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideFerulic acid may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidAminosalicylic Acid may increase the anticoagulant activities of Ferulic acid.Approved
AmlodipineAmlodipine may increase the hypotensive activities of Ferulic acid.Approved
AmphetamineAmphetamine may increase the hypotensive activities of Ferulic acid.Approved, Illicit, Investigational
AmrubicinFerulic acid may decrease the excretion rate of Amrubicin which could result in a higher serum level.Approved, Investigational
AnagrelideAnagrelide may increase the anticoagulant activities of Ferulic acid.Approved
AncrodFerulic acid may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideAndrographolide may increase the anticoagulant activities of Ferulic acid.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with anecortave acetate.Investigational
AnisodamineAnisodamine may increase the anticoagulant activities of Ferulic acid.Investigational
AnistreplaseAnistreplase may increase the anticoagulant activities of Ferulic acid.Approved
AnnamycinFerulic acid may decrease the excretion rate of Annamycin which could result in a higher serum level.Investigational
AntipyrineAntipyrine may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
Antithrombin III humanFerulic acid may increase the anticoagulant activities of Antithrombin III human.Approved
ApixabanApixaban may increase the anticoagulant activities of Ferulic acid.Approved
ApocyninApocynin may increase the anticoagulant activities of Ferulic acid.Investigational
ApramycinFerulic acid may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastApremilast may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
ArbekacinFerulic acid may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinFerulic acid may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanFerulic acid may increase the anticoagulant activities of Argatroban.Approved, Investigational
ArotinololFerulic acid may decrease the antihypertensive activities of Arotinolol.Investigational
AstaxanthinAstaxanthin may increase the anticoagulant activities of Ferulic acid.Investigational
AtamestaneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Atamestane.Investigational
AtenololAtenolol may increase the hypotensive activities of Ferulic acid.Approved
AvanafilAvanafil may increase the antihypertensive activities of Ferulic acid.Approved
AzapropazoneAzapropazone may increase the anticoagulant activities of Ferulic acid.Withdrawn
AzelastineAzelastine may increase the anticoagulant activities of Ferulic acid.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Ferulic acid.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Ferulic acid.Investigational
BalsalazideFerulic acid may increase the nephrotoxic activities of Balsalazide.Approved, Investigational
BarnidipineFerulic acid may increase the antihypertensive activities of Barnidipine.Approved
BatroxobinBatroxobin may increase the anticoagulant activities of Ferulic acid.Experimental
BecaplerminFerulic acid may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololFerulic acid may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinFerulic acid may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BemiparinBemiparin may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
BenazeprilBenazepril may increase the hypotensive activities of Ferulic acid.Approved, Investigational
BendazacBendazac may increase the anticoagulant activities of Ferulic acid.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Ferulic acid.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Ferulic acid.Withdrawn
BenorilateBenorilate may increase the anticoagulant activities of Ferulic acid.Experimental
BenoxaprofenBenoxaprofen may increase the anticoagulant activities of Ferulic acid.Withdrawn
BenzydamineBenzydamine may increase the anticoagulant activities of Ferulic acid.Approved
BepridilBepridil may increase the hypotensive activities of Ferulic acid.Approved, Withdrawn
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Ferulic acid.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Betamethasone.Approved, Vet Approved
BetaxololBetaxolol may increase the hypotensive activities of Ferulic acid.Approved, Investigational
BethanidineBethanidine may increase the hypotensive activities of Ferulic acid.Approved
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Ferulic acid.Approved, Investigational
BevantololFerulic acid may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumBevonium may increase the anticoagulant activities of Ferulic acid.Experimental
BietaserpineBietaserpine may increase the hypotensive activities of Ferulic acid.Experimental
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Ferulic acid.Approved, Investigational
BisoprololBisoprolol may increase the hypotensive activities of Ferulic acid.Approved
BivalirudinFerulic acid may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BopindololFerulic acid may decrease the antihypertensive activities of Bopindolol.Approved
BosentanBosentan may increase the hypotensive activities of Ferulic acid.Approved, Investigational
BQ-123Ferulic acid may increase the hypotensive activities of BQ-123.Investigational
BretyliumBretylium may increase the hypotensive activities of Ferulic acid.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Ferulic acid.Approved
BrinaseBrinase may increase the anticoagulant activities of Ferulic acid.Experimental
BrofaromineBrofaromine may increase the hypotensive activities of Ferulic acid.Experimental
BromfenacBromfenac may increase the anticoagulant activities of Ferulic acid.Approved
BucillamineBucillamine may increase the anticoagulant activities of Ferulic acid.Investigational
BucindololFerulic acid may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Budesonide.Approved
BufexamacBufexamac may increase the anticoagulant activities of Ferulic acid.Approved, Experimental
BuflomedilBuflomedil may increase the anticoagulant activities of Ferulic acid.Experimental
BufuralolFerulic acid may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneBumadizone may increase the anticoagulant activities of Ferulic acid.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Ferulic acid.Approved
BupranololFerulic acid may increase the hypotensive activities of Bupranolol.Approved
ButylphthalideButylphthalide may increase the anticoagulant activities of Ferulic acid.Investigational
CadralazineCadralazine may increase the hypotensive activities of Ferulic acid.Experimental
CafedrineFerulic acid may increase the hypotensive activities of Cafedrine.Investigational
CandesartanFerulic acid may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilCandesartan cilexetil may increase the hypotensive activities of Ferulic acid.Approved
CandoxatrilCandoxatril may increase the hypotensive activities of Ferulic acid.Experimental
CangrelorCangrelor may increase the anticoagulant activities of Ferulic acid.Approved
CaplacizumabCaplacizumab may increase the anticoagulant activities of Ferulic acid.Investigational
CaptoprilCaptopril may increase the hypotensive activities of Ferulic acid.Approved
Carbaspirin calciumCarbaspirin calcium may increase the anticoagulant activities of Ferulic acid.Experimental, Investigational
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Ferulic acid.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Ferulic acid.Withdrawn
CarprofenCarprofen may increase the anticoagulant activities of Ferulic acid.Approved, Vet Approved, Withdrawn
CarteololCarteolol may increase the hypotensive activities of Ferulic acid.Approved
CarvedilolCarvedilol may increase the hypotensive activities of Ferulic acid.Approved, Investigational
CastanospermineCastanospermine may increase the anticoagulant activities of Ferulic acid.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Celecoxib.Approved, Investigational
CeliprololCeliprolol may increase the hypotensive activities of Ferulic acid.Approved, Investigational
CertoparinFerulic acid may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChloroquineChloroquine may increase the anticoagulant activities of Ferulic acid.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Ferulic acid.Approved, Vet Approved
ChlorotrianiseneChlorotrianisene may decrease the anticoagulant activities of Ferulic acid.Investigational, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Ferulic acid.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Ferulic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateCholine magnesium trisalicylate may increase the anticoagulant activities of Ferulic acid.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Ciclesonide.Approved, Investigational
CicletanineFerulic acid may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilCilazapril may increase the hypotensive activities of Ferulic acid.Approved
CilostazolCilostazol may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
CinoxacinFerulic acid may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
Citric AcidFerulic acid may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
ClobetasolThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the hypotensive activities of Ferulic acid.Approved
ClonixinClonixin may increase the anticoagulant activities of Ferulic acid.Approved
ClopidogrelClopidogrel may increase the anticoagulant activities of Ferulic acid.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Ferulic acid.Vet Approved
CloranololFerulic acid may increase the hypotensive activities of Cloranolol.Experimental
CloricromenCloricromen may increase the anticoagulant activities of Ferulic acid.Experimental
ClorindioneClorindione may increase the anticoagulant activities of Ferulic acid.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Ferulic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Ferulic acid resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Collagenase clostridium histolyticumThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Collagenase clostridium histolyticum.Approved, Investigational
Conjugated estrogensConjugated estrogens may decrease the anticoagulant activities of Ferulic acid.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Cortisone acetate.Approved, Investigational
CryptenamineCryptenamine may increase the hypotensive activities of Ferulic acid.Approved
CurcuminCurcumin may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Ferulic acid.Experimental
CyclosporineFerulic acid may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideCyclothiazide may increase the hypotensive activities of Ferulic acid.Approved
Dabigatran etexilateDabigatran etexilate may increase the anticoagulant activities of Ferulic acid.Approved
DaidzeinDaidzein may decrease the anticoagulant activities of Ferulic acid.Experimental
DalteparinFerulic acid may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidFerulic acid may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanFerulic acid may increase the anticoagulant activities of Darexaban.Investigational
DasatinibDasatinib may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
DaunorubicinFerulic acid may decrease the excretion rate of Daunorubicin which could result in a higher serum level.Approved
DebrisoquinDebrisoquin may increase the hypotensive activities of Ferulic acid.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Deferasirox.Approved, Investigational
DefibrotideDefibrotide may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Deflazacort.Approved, Investigational
DelaprilFerulic acid may increase the hypotensive activities of Delapril.Experimental
DemegestoneThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Demegestone.Experimental
Deoxycholic AcidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Deoxycholic Acid.Approved
DersalazineDersalazine may increase the anticoagulant activities of Ferulic acid.Investigational
DeserpidineFerulic acid may increase the hypotensive activities of Deserpidine.Approved
DesirudinFerulic acid may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Desmopressin.Approved
DesmoteplaseDesmoteplase may increase the anticoagulant activities of Ferulic acid.Investigational
DesogestrelThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Desogestrel.Approved
DesonideThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Dexamethasone isonicotinate.Vet Approved
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Ferulic acid.Approved, Investigational
DextranFerulic acid may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
Dextran 40Ferulic acid may increase the anticoagulant activities of Dextran 40.Approved
Dextran 70Ferulic acid may increase the anticoagulant activities of Dextran 70.Approved
Dextran 75Ferulic acid may increase the anticoagulant activities of Dextran 75.Approved
DiazoxideDiazoxide may increase the hypotensive activities of Ferulic acid.Approved
DibekacinFerulic acid may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Ferulic acid.Approved, Vet Approved
DicoumarolFerulic acid may increase the anticoagulant activities of Dicoumarol.Approved
DienestrolDienestrol may decrease the anticoagulant activities of Ferulic acid.Approved, Investigational
DienogestThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Dienogest.Approved
DiethylnorspermineDiethylnorspermine may increase the hypotensive activities of Ferulic acid.Investigational
DiethylstilbestrolDiethylstilbestrol may decrease the anticoagulant activities of Ferulic acid.Approved, Investigational
DifenpiramideDifenpiramide may increase the anticoagulant activities of Ferulic acid.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Diflorasone.Approved
DiflunisalDiflunisal may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Ferulic acid.Approved
DihydralazineDihydralazine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
DihydrostreptomycinFerulic acid may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DiltiazemDiltiazem may increase the hypotensive activities of Ferulic acid.Approved, Investigational
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Ferulic acid.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Ferulic acid.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Ferulic acid.Approved
DiphenadioneDiphenadione may increase the anticoagulant activities of Ferulic acid.Experimental
DipyridamoleDipyridamole may increase the anticoagulant activities of Ferulic acid.Approved
DitazoleDitazole may increase the anticoagulant activities of Ferulic acid.Approved, Withdrawn
DorzolamideDorzolamide may increase the hypotensive activities of Ferulic acid.Approved
DoxazosinDoxazosin may increase the hypotensive activities of Ferulic acid.Approved
DoxorubicinFerulic acid may decrease the excretion rate of Doxorubicin which could result in a higher serum level.Approved, Investigational
DrospirenoneFerulic acid may increase the hyperkalemic activities of Drospirenone.Approved
Drotrecogin alfaDrotrecogin alfa may increase the anticoagulant activities of Ferulic acid.Approved, Investigational, Withdrawn
DroxicamDroxicam may increase the anticoagulant activities of Ferulic acid.Withdrawn
DuvelisibDuvelisib may increase the anticoagulant activities of Ferulic acid.Investigational
DydrogesteroneThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Dydrogesterone.Approved, Investigational, Withdrawn
E-6201E-6201 may increase the anticoagulant activities of Ferulic acid.Investigational
Edetic AcidFerulic acid may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanEdoxaban may increase the anticoagulant activities of Ferulic acid.Approved
EfonidipineFerulic acid may increase the hypotensive activities of Efonidipine.Approved, Investigational
EnalaprilEnalapril may increase the hypotensive activities of Ferulic acid.Approved, Vet Approved
EnalaprilatFerulic acid may increase the hypotensive activities of Enalaprilat.Approved
EndralazineEndralazine may increase the hypotensive activities of Ferulic acid.Experimental
EnoxacinFerulic acid may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinFerulic acid may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Ferulic acid.Experimental
EpanololFerulic acid may increase the hypotensive activities of Epanolol.Experimental
EpimestrolEpimestrol may decrease the anticoagulant activities of Ferulic acid.Experimental
EpinastineEpinastine may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
EpirizoleEpirizole may increase the anticoagulant activities of Ferulic acid.Approved
EpirubicinFerulic acid may decrease the excretion rate of Epirubicin which could result in a higher serum level.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Ferulic acid.Experimental
EplerenoneFerulic acid may decrease the antihypertensive activities of Eplerenone.Approved
EplivanserinEplivanserin may increase the anticoagulant activities of Ferulic acid.Investigational
eplivanserineeplivanserine may increase the anticoagulant activities of Ferulic acid.Investigational
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Ferulic acid.Approved
EprosartanEprosartan may increase the hypotensive activities of Ferulic acid.Approved
EptifibatideEptifibatide may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
EquileninThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Equilin.Approved
EquolEquol may decrease the anticoagulant activities of Ferulic acid.Investigational
EsmololFerulic acid may decrease the antihypertensive activities of Esmolol.Approved
EstradiolEstradiol may decrease the anticoagulant activities of Ferulic acid.Approved, Investigational, Vet Approved
Estradiol acetateEstradiol acetate may decrease the anticoagulant activities of Ferulic acid.Approved, Investigational, Vet Approved
Estradiol cypionateEstradiol cypionate may decrease the anticoagulant activities of Ferulic acid.Approved, Investigational, Vet Approved
Estradiol valerateEstradiol valerate may decrease the anticoagulant activities of Ferulic acid.Approved, Investigational, Vet Approved
EstriolEstriol may decrease the anticoagulant activities of Ferulic acid.Approved, Investigational, Vet Approved
Estrogens, esterifiedEstrogens, esterified may decrease the anticoagulant activities of Ferulic acid.Approved
EstroneEstrone may decrease the anticoagulant activities of Ferulic acid.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Ferulic acid.Approved, Investigational
EtanerceptEtanercept may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
EthenzamideEthenzamide may increase the anticoagulant activities of Ferulic acid.Experimental
Ethinyl EstradiolEthinyl Estradiol may decrease the anticoagulant activities of Ferulic acid.Approved
Ethyl biscoumacetateFerulic acid may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
EtonogestrelThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Etonogestrel.Approved, Investigational
EtoricoxibThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Etoricoxib.Approved, Investigational
Evening primrose oilEvening primrose oil may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
ExisulindExisulind may increase the anticoagulant activities of Ferulic acid.Investigational
FelbinacFelbinac may increase the anticoagulant activities of Ferulic acid.Experimental
FelodipineFelodipine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
FenbufenFenbufen may increase the anticoagulant activities of Ferulic acid.Approved
FenoldopamFenoldopam may increase the hypotensive activities of Ferulic acid.Approved
FenoprofenFenoprofen may increase the anticoagulant activities of Ferulic acid.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Ferulic acid.Vet Approved
FentiazacFentiazac may increase the anticoagulant activities of Ferulic acid.Experimental
FeprazoneFeprazone may increase the anticoagulant activities of Ferulic acid.Experimental
FibrinolysinFibrinolysin may increase the anticoagulant activities of Ferulic acid.Investigational
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Ferulic acid.Approved, Investigational
FleroxacinFerulic acid may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Ferulic acid.Approved, Withdrawn
FluasteroneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fluasterone.Investigational
FludrocortisoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fludrocortisone.Approved, Investigational
FluindioneFerulic acid may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineFerulic acid may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Flunisolide.Approved, Investigational
FlunixinFlunixin may increase the anticoagulant activities of Ferulic acid.Vet Approved
FlunoxaprofenFlunoxaprofen may increase the anticoagulant activities of Ferulic acid.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fluorometholone.Approved, Investigational
FluprednideneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Ferulic acid.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Flurandrenolide.Approved
FlurbiprofenFlurbiprofen may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Ferulic acid.Approved, Nutraceutical, Vet Approved
FondaparinuxFerulic acid may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumFerulic acid may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Ferulic acid.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilFosinopril may increase the hypotensive activities of Ferulic acid.Approved
FramycetinFerulic acid may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Ferulic acid.Approved, Investigational, Vet Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Ferulic acid.Approved, Vet Approved
GabexateFerulic acid may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinFerulic acid may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinFerulic acid may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Ferulic acid.Approved, Withdrawn
GemifloxacinFerulic acid may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
GeneticinFerulic acid may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GenisteinGenistein may decrease the anticoagulant activities of Ferulic acid.Investigational
GentamicinFerulic acid may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AFerulic acid may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GestodeneThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Gestodene.Approved, Investigational
GestonoroneThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Gestonorone.Experimental
GestrinoneThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Gestrinone.Approved
GPX-150Ferulic acid may decrease the excretion rate of GPX-150 which could result in a higher serum level.Investigational
GrepafloxacinFerulic acid may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalGuacetisal may increase the anticoagulant activities of Ferulic acid.Experimental
GuanabenzGuanabenz may increase the hypotensive activities of Ferulic acid.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Ferulic acid.Approved
GuanazodineFerulic acid may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineGuanethidine may increase the hypotensive activities of Ferulic acid.Approved
GuanfacineGuanfacine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
GuanoclorFerulic acid may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzFerulic acid may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanFerulic acid may increase the hypotensive activities of Guanoxan.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Haloperidol.Approved
HarmalineHarmaline may increase the hypotensive activities of Ferulic acid.Experimental
HE3286The risk or severity of adverse effects can be increased when Ferulic acid is combined with HE3286.Investigational
HeminHemin may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
Hemoglobin crosfumarilHemoglobin crosfumaril may increase the anticoagulant activities of Ferulic acid.Experimental
HeparinFerulic acid may increase the anticoagulant activities of Heparin.Approved, Investigational
HexamethoniumFerulic acid may increase the hypotensive activities of Hexamethonium.Experimental
HexestrolHexestrol may decrease the anticoagulant activities of Ferulic acid.Withdrawn
HigenamineHigenamine may increase the anticoagulant activities of Ferulic acid.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Ferulic acid.Experimental
HydralazineFerulic acid may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Ferulic acid.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Ferulic acid.Approved, Investigational
Hydroxyprogesterone caproateThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Hydroxyprogesterone caproate.Approved, Investigational
HydroxytyrosolHydroxytyrosol may increase the anticoagulant activities of Ferulic acid.Investigational
Hygromycin BFerulic acid may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of adverse effects can be increased when Ibrutinib is combined with Ferulic acid.Approved
IbudilastIbudilast may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
IbuprofenIbuprofen may increase the anticoagulant activities of Ferulic acid.Approved
IbuproxamIbuproxam may increase the anticoagulant activities of Ferulic acid.Withdrawn
IcatibantIcatibant may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
Icosapent ethylIcosapent ethyl may increase the anticoagulant activities of Ferulic acid.Approved, Investigational, Nutraceutical
IdarubicinFerulic acid may decrease the excretion rate of Idarubicin which could result in a higher serum level.Approved
IdraparinuxFerulic acid may increase the anticoagulant activities of Idraparinux.Investigational
IfenprodilIfenprodil may increase the anticoagulant activities of Ferulic acid.Approved, Investigational, Withdrawn
IfetrobanIfetroban may increase the anticoagulant activities of Ferulic acid.Investigational
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Ferulic acid.Approved, Investigational
ImidaprilFerulic acid may increase the hypotensive activities of Imidapril.Investigational
Imidazole salicylateImidazole salicylate may increase the anticoagulant activities of Ferulic acid.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Ferulic acid.Approved
IndenololFerulic acid may increase the hypotensive activities of Indenolol.Withdrawn
IndobufenIndobufen may increase the anticoagulant activities of Ferulic acid.Investigational
IndomethacinIndomethacin may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
IndoprofenIndoprofen may increase the anticoagulant activities of Ferulic acid.Withdrawn
IndoraminIndoramin may increase the hypotensive activities of Ferulic acid.Withdrawn
IproclozideIproclozide may increase the hypotensive activities of Ferulic acid.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Ferulic acid.Withdrawn
IrbesartanIrbesartan may increase the hypotensive activities of Ferulic acid.Approved, Investigational
IsepamicinFerulic acid may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Ferulic acid.Approved
IsoxicamIsoxicam may increase the anticoagulant activities of Ferulic acid.Withdrawn
IsradipineIsradipine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
IstaroximeThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Istaroxime.Investigational
KanamycinFerulic acid may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneKebuzone may increase the anticoagulant activities of Ferulic acid.Experimental
KetanserinKetanserin may increase the anticoagulant activities of Ferulic acid.Investigational
KetoprofenKetoprofen may increase the anticoagulant activities of Ferulic acid.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Ferulic acid.Approved
LabetalolLabetalol may increase the hypotensive activities of Ferulic acid.Approved
LacidipineFerulic acid may increase the hypotensive activities of Lacidipine.Approved, Investigational
LandiololFerulic acid may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Ferulic acid.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Ferulic acid.Approved, Investigational
LeflunomideLeflunomide may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
LepirudinFerulic acid may increase the anticoagulant activities of Lepirudin.Approved
LercanidipineLercanidipine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
LetaxabanFerulic acid may increase the anticoagulant activities of Letaxaban.Investigational
LevobunololFerulic acid may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinFerulic acid may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LevonorgestrelThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Levonorgestrel.Approved, Investigational
LimaprostThe risk or severity of adverse effects can be increased when Limaprost is combined with Ferulic acid.Approved, Investigational
LinsidomineLinsidomine may increase the anticoagulant activities of Ferulic acid.Experimental
LisinoprilLisinopril may increase the hypotensive activities of Ferulic acid.Approved, Investigational
LisofyllineLisofylline may increase the anticoagulant activities of Ferulic acid.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Ferulic acid.Approved
LofexidineLofexidine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
LonazolacLonazolac may increase the anticoagulant activities of Ferulic acid.Experimental
LornoxicamLornoxicam may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
LosartanLosartan may increase the hypotensive activities of Ferulic acid.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Loteprednol.Approved
LoxoprofenLoxoprofen may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Ferulic acid.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Ferulic acid.Vet Approved
MacitentanFerulic acid may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may increase the anticoagulant activities of Ferulic acid.Approved
ManidipineFerulic acid may increase the hypotensive activities of Manidipine.Approved, Investigational
MasoprocolMasoprocol may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Ferulic acid is combined with ME-609.Investigational
MebanazineMebanazine may increase the hypotensive activities of Ferulic acid.Withdrawn
MecamylamineMecamylamine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
Meclofenamic acidMeclofenamic acid may increase the anticoagulant activities of Ferulic acid.Approved, Vet Approved
MedrogestoneThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Medrogestone.Approved
Medroxyprogesterone acetateThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Medroxyprogesterone acetate.Approved, Investigational
MedrysoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Medrysone.Approved
Mefenamic acidMefenamic acid may increase the anticoagulant activities of Ferulic acid.Approved
Megestrol acetateThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Megestrol acetate.Approved, Investigational, Vet Approved
MelagatranFerulic acid may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Melengestrol.Vet Approved
MeloxicamMeloxicam may increase the anticoagulant activities of Ferulic acid.Approved, Vet Approved
MepindololFerulic acid may decrease the antihypertensive activities of Mepindolol.Experimental
MesalazineFerulic acid may increase the nephrotoxic activities of Mesalazine.Approved
MestranolMestranol may decrease the anticoagulant activities of Ferulic acid.Approved
MetamizoleMetamizole may increase the anticoagulant activities of Ferulic acid.Approved, Investigational, Withdrawn
MethallenestrilMethallenestril may decrease the anticoagulant activities of Ferulic acid.Experimental
MethoserpidineFerulic acid may increase the hypotensive activities of Methoserpidine.Experimental
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Ferulic acid.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Ferulic acid.Approved
Methyl salicylateMethyl salicylate may increase the anticoagulant activities of Ferulic acid.Approved, Vet Approved
MethyldopaMethyldopa may increase the hypotensive activities of Ferulic acid.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Ferulic acid.Approved, Investigational
MethylestrenoloneThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Methylestrenolone.Experimental
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Ferulic acid.Approved, Investigational
MethylprednisoloneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Methylprednisolone.Approved, Vet Approved
MetipranololMetipranolol may increase the hypotensive activities of Ferulic acid.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Ferulic acid.Approved
MetoprololMetoprolol may increase the hypotensive activities of Ferulic acid.Approved, Investigational
MetrizamideFerulic acid may decrease the excretion rate of Metrizamide which could result in a higher serum level.Approved
MetyrosineFerulic acid may increase the hypotensive activities of Metyrosine.Approved
MibefradilMibefradil may increase the hypotensive activities of Ferulic acid.Investigational, Withdrawn
MicronomicinFerulic acid may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Ferulic acid.Approved, Experimental
MilrinoneMilrinone may increase the anticoagulant activities of Ferulic acid.Approved
MinaprineMinaprine may increase the hypotensive activities of Ferulic acid.Approved
MinoxidilMinoxidil may increase the hypotensive activities of Ferulic acid.Approved, Investigational
MirodenafilMirodenafil may increase the antihypertensive activities of Ferulic acid.Investigational
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Ferulic acid.Approved
MizoribineMizoribine may increase the anticoagulant activities of Ferulic acid.Investigational
MoclobemideMoclobemide may increase the hypotensive activities of Ferulic acid.Approved, Investigational
MoexiprilMoexipril may increase the hypotensive activities of Ferulic acid.Approved
MofebutazoneMofebutazone may increase the anticoagulant activities of Ferulic acid.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
MometasoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Ferulic acid.Approved
MoxestrolMoxestrol may decrease the anticoagulant activities of Ferulic acid.Experimental
MoxonidineMoxonidine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
MuzolimineFerulic acid may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
Mycophenolic acidMycophenolic acid may increase the anticoagulant activities of Ferulic acid.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Nabumetone.Approved
NadololNadolol may increase the hypotensive activities of Ferulic acid.Approved
NadroparinFerulic acid may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatFerulic acid may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineNaftifine may increase the anticoagulant activities of Ferulic acid.Approved
NaftopidilNaftopidil may increase the anticoagulant activities of Ferulic acid.Investigational
Nalidixic AcidFerulic acid may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenNaproxen may increase the anticoagulant activities of Ferulic acid.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Ferulic acid is combined with NCX 1022.Investigational
NeamineFerulic acid may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololNebivolol may increase the hypotensive activities of Ferulic acid.Approved, Investigational
NemonoxacinFerulic acid may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinFerulic acid may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacNepafenac may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
NetilmicinFerulic acid may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NialamideNialamide may increase the hypotensive activities of Ferulic acid.Withdrawn
NicardipineNicardipine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
NicorandilFerulic acid may increase the hypotensive activities of Nicorandil.Approved, Investigational
NifenazoneNifenazone may increase the anticoagulant activities of Ferulic acid.Experimental
Niflumic AcidNiflumic Acid may increase the anticoagulant activities of Ferulic acid.Approved
NiguldipineFerulic acid may increase the hypotensive activities of Niguldipine.Experimental
NilvadipineNilvadipine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
NimesulideNimesulide may increase the anticoagulant activities of Ferulic acid.Approved, Investigational, Withdrawn
NimodipineNimodipine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
NintedanibThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Nintedanib.Approved
NisoldipineNisoldipine may increase the hypotensive activities of Ferulic acid.Approved
NitrendipineNitrendipine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
NitroaspirinNitroaspirin may increase the anticoagulant activities of Ferulic acid.Investigational
NitroprussideNitroprusside may increase the hypotensive activities of Ferulic acid.Approved, Investigational
NomegestrolThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Nomegestrol.Approved
NorethisteroneThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Norethisterone.Approved
NorfloxacinFerulic acid may increase the neuroexcitatory activities of Norfloxacin.Approved
NorgestrienoneThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Norgestrienone.Experimental
ObinutuzumabFerulic acid may increase the hypotensive activities of Obinutuzumab.Approved, Investigational
OctamoxinOctamoxin may increase the hypotensive activities of Ferulic acid.Withdrawn
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Oleoyl-estrone.Investigational
OlmesartanOlmesartan may increase the hypotensive activities of Ferulic acid.Approved, Investigational
OlopatadineOlopatadine may increase the anticoagulant activities of Ferulic acid.Approved
OlsalazineFerulic acid may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Ferulic acid is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatOmapatrilat may increase the hypotensive activities of Ferulic acid.Investigational
Omega-3 fatty acidsOmega-3 fatty acids may increase the anticoagulant activities of Ferulic acid.Approved, Nutraceutical
OrgoteinOrgotein may increase the anticoagulant activities of Ferulic acid.Vet Approved
OtamixabanFerulic acid may increase the anticoagulant activities of Otamixaban.Investigational
OxaprozinOxaprozin may increase the anticoagulant activities of Ferulic acid.Approved
Oxolinic acidFerulic acid may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololOxprenolol may increase the hypotensive activities of Ferulic acid.Approved
OxyphenbutazoneOxyphenbutazone may increase the anticoagulant activities of Ferulic acid.Approved, Withdrawn
OzagrelOzagrel may increase the anticoagulant activities of Ferulic acid.Investigational
PamidronateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Parecoxib.Approved
PargylinePargyline may increase the hypotensive activities of Ferulic acid.Approved
ParnaparinParnaparin may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
ParomomycinFerulic acid may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideParthenolide may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
PazufloxacinFerulic acid may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinFerulic acid may increase the neuroexcitatory activities of Pefloxacin.Approved
PenbutololPenbutolol may increase the hypotensive activities of Ferulic acid.Approved, Investigational
Pentaerythritol TetranitrateFerulic acid may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
PentoliniumPentolinium may increase the hypotensive activities of Ferulic acid.Approved
Pentosan PolysulfatePentosan Polysulfate may increase the anticoagulant activities of Ferulic acid.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Ferulic acid.Approved, Investigational
PerindoprilPerindopril may increase the hypotensive activities of Ferulic acid.Approved
PhenelzinePhenelzine may increase the hypotensive activities of Ferulic acid.Approved
PhenindioneFerulic acid may increase the anticoagulant activities of Phenindione.Approved, Investigational
PheniprazinePheniprazine may increase the hypotensive activities of Ferulic acid.Withdrawn
PhenoxybenzaminePhenoxybenzamine may increase the hypotensive activities of Ferulic acid.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Ferulic acid.Withdrawn
PhenprocoumonFerulic acid may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhentolaminePhentolamine may increase the hypotensive activities of Ferulic acid.Approved
Phenyl aminosalicylatePhenyl aminosalicylate may increase the anticoagulant activities of Ferulic acid.Approved
PhenylbutazonePhenylbutazone may increase the anticoagulant activities of Ferulic acid.Approved, Vet Approved
PicotamidePicotamide may increase the anticoagulant activities of Ferulic acid.Experimental
PimecrolimusPimecrolimus may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
PinacidilPinacidil may increase the hypotensive activities of Ferulic acid.Approved
PindololPindolol may increase the hypotensive activities of Ferulic acid.Approved, Investigational
Pipemidic acidFerulic acid may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PirarubicinFerulic acid may decrease the excretion rate of Pirarubicin which could result in a higher serum level.Investigational
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Ferulic acid.Approved
PirfenidonePirfenidone may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Ferulic acid.Approved
Piromidic acidFerulic acid may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamPiroxicam may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
PirprofenPirprofen may increase the anticoagulant activities of Ferulic acid.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Pitolisant.Approved, Investigational
PivhydrazinePivhydrazine may increase the hypotensive activities of Ferulic acid.Withdrawn
Platelet Activating FactorPlatelet Activating Factor may increase the hypotensive activities of Ferulic acid.Experimental
PlazomicinFerulic acid may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PlicamycinFerulic acid may decrease the excretion rate of Plicamycin which could result in a higher serum level.Approved, Investigational, Withdrawn
Polyestradiol phosphatePolyestradiol phosphate may decrease the anticoagulant activities of Ferulic acid.Approved
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Ferulic acid.Approved
PractololFerulic acid may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Ferulic acid.Approved, Investigational
PranoprofenPranoprofen may increase the anticoagulant activities of Ferulic acid.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Prasterone sulfate.Investigational
PrasugrelPrasugrel may increase the anticoagulant activities of Ferulic acid.Approved
PrazosinPrazosin may increase the hypotensive activities of Ferulic acid.Approved
PrednicarbateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Ferulic acid can be increased when it is combined with Probenecid.Approved, Investigational
ProcarbazineProcarbazine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
ProgesteroneThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Progesterone.Approved, Vet Approved
ProglumetacinProglumetacin may increase the anticoagulant activities of Ferulic acid.Experimental
PromegestoneThe therapeutic efficacy of Ferulic acid can be decreased when used in combination with Promegestone.Experimental
PromestrienePromestriene may decrease the anticoagulant activities of Ferulic acid.Investigational
PropacetamolPropacetamol may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
PropranololPropranolol may increase the hypotensive activities of Ferulic acid.Approved, Investigational
PropyphenazonePropyphenazone may increase the anticoagulant activities of Ferulic acid.Experimental
ProquazoneProquazone may increase the anticoagulant activities of Ferulic acid.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Ferulic acid.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Ferulic acid.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Ferulic acid.Vet Approved
Protein CFerulic acid may increase the anticoagulant activities of Protein C.Approved
Protein S humanFerulic acid may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeFerulic acid may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinFerulic acid may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299PTC299 may increase the anticoagulant activities of Ferulic acid.Investigational
PuromycinFerulic acid may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilQuinapril may increase the hypotensive activities of Ferulic acid.Approved, Investigational
QuinestrolQuinestrol may decrease the anticoagulant activities of Ferulic acid.Approved
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Ferulic acid.Approved
QuinineQuinine may increase the hypotensive activities of Ferulic acid.Approved
RamatrobanRamatroban may increase the anticoagulant activities of Ferulic acid.Investigational
RamiprilRamipril may increase the hypotensive activities of Ferulic acid.Approved
RasagilineRasagiline may increase the hypotensive activities of Ferulic acid.Approved
RelcovaptanRelcovaptan may increase the anticoagulant activities of Ferulic acid.Investigational
RemikirenRemikiren may increase the hypotensive activities of Ferulic acid.Approved
RescinnamineFerulic acid may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
ResveratrolResveratrol may increase the anticoagulant activities of Ferulic acid.Approved, Experimental, Investigational
ReteplaseReteplase may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
ReviparinFerulic acid may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinFerulic acid may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RidogrelRidogrel may increase the anticoagulant activities of Ferulic acid.Approved
RilmenidineRilmenidine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
RimexoloneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Rimexolone.Approved
RiociguatFerulic acid may increase the hypotensive activities of Riociguat.Approved
RisedronateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Risedronate.Approved, Investigational
RituximabFerulic acid may increase the hypotensive activities of Rituximab.Approved
RivaroxabanFerulic acid may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosiglitazoneRosiglitazone may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
RosoxacinFerulic acid may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinFerulic acid may increase the neuroexcitatory activities of Rufloxacin.Experimental
SabarubicinFerulic acid may decrease the excretion rate of Sabarubicin which could result in a higher serum level.Investigational
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Ferulic acid.Approved
SafrazineSafrazine may increase the hypotensive activities of Ferulic acid.Withdrawn
SalicylamideSalicylamide may increase the anticoagulant activities of Ferulic acid.Approved
Salicylic acidSalicylic acid may increase the anticoagulant activities of Ferulic acid.Approved, Investigational, Vet Approved
SalsalateSalsalate may increase the anticoagulant activities of Ferulic acid.Approved
SaprisartanSaprisartan may increase the hypotensive activities of Ferulic acid.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Ferulic acid.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Ferulic acid.Approved, Investigational
SarpogrelateSarpogrelate may increase the anticoagulant activities of Ferulic acid.Investigational
SaruplaseSaruplase may increase the anticoagulant activities of Ferulic acid.Experimental
SecoisolariciresinolSecoisolariciresinol may decrease the anticoagulant activities of Ferulic acid.Investigational
SelegilineSelegiline may increase the hypotensive activities of Ferulic acid.Approved, Investigational, Vet Approved
SelexipagSelexipag may increase the anticoagulant activities of Ferulic acid.Approved
SemapimodSemapimod may increase the anticoagulant activities of Ferulic acid.Investigational
SeratrodastSeratrodast may increase the anticoagulant activities of Ferulic acid.Approved
SerrapeptaseSerrapeptase may increase the anticoagulant activities of Ferulic acid.Investigational
SevofluraneSevoflurane may increase the anticoagulant activities of Ferulic acid.Approved, Vet Approved
SildenafilSildenafil may increase the antihypertensive activities of Ferulic acid.Approved, Investigational
SisomicinFerulic acid may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinFerulic acid may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
SitaxentanFerulic acid may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Ferulic acid.Approved
SotalolFerulic acid may decrease the antihypertensive activities of Sotalol.Approved
SP1049CFerulic acid may decrease the excretion rate of SP1049C which could result in a higher serum level.Investigational
SparfloxacinFerulic acid may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpectinomycinFerulic acid may decrease the excretion rate of Spectinomycin which could result in a higher serum level.Approved, Investigational, Vet Approved
SpiraprilSpirapril may increase the hypotensive activities of Ferulic acid.Approved
SpironolactoneFerulic acid may decrease the antihypertensive activities of Spironolactone.Approved
SRT501SRT501 may increase the anticoagulant activities of Ferulic acid.Investigational
StreptokinaseStreptokinase may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
StreptomycinFerulic acid may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinFerulic acid may decrease the excretion rate of Streptozocin which could result in a higher serum level.Approved, Investigational
SugammadexSugammadex may increase the anticoagulant activities of Ferulic acid.Approved
SulfasalazineSulfasalazine may increase the anticoagulant activities of Ferulic acid.Approved
SulindacSulindac may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
SulodexideFerulic acid may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Ferulic acid.Investigational
SuprofenSuprofen may increase the anticoagulant activities of Ferulic acid.Approved, Withdrawn
SuxibuzoneSuxibuzone may increase the anticoagulant activities of Ferulic acid.Experimental
Synthetic Conjugated Estrogens, ASynthetic Conjugated Estrogens, A may decrease the anticoagulant activities of Ferulic acid.Approved
Synthetic Conjugated Estrogens, BSynthetic Conjugated Estrogens, B may decrease the anticoagulant activities of Ferulic acid.Approved
TacrolimusFerulic acid may increase the nephrotoxic activities of Tacrolimus.Approved, Investigational
TadalafilTadalafil may increase the antihypertensive activities of Ferulic acid.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Ferulic acid.Approved
TalinololFerulic acid may increase the hypotensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Ferulic acid.Approved
TarenflurbilTarenflurbil may increase the anticoagulant activities of Ferulic acid.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Ferulic acid.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Technetium Tc-99m medronate.Approved
TelmisartanTelmisartan may increase the hypotensive activities of Ferulic acid.Approved, Investigational
TemafloxacinFerulic acid may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilFerulic acid may increase the hypotensive activities of Temocapril.Experimental, Investigational
TenecteplaseTenecteplase may increase the anticoagulant activities of Ferulic acid.Approved
TenidapTenidap may increase the anticoagulant activities of Ferulic acid.Experimental
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamTenoxicam may increase the anticoagulant activities of Ferulic acid.Approved
TepoxalinTepoxalin may increase the anticoagulant activities of Ferulic acid.Vet Approved
TeriflunomideTeriflunomide may increase the anticoagulant activities of Ferulic acid.Approved
TerlipressinTerlipressin may increase the hypotensive activities of Ferulic acid.Approved, Investigational
TertatololFerulic acid may decrease the antihypertensive activities of Tertatolol.Experimental
TesmilifeneTesmilifene may increase the anticoagulant activities of Ferulic acid.Investigational
Testosterone cypionateThe therapeutic efficacy of Ferulic acid can be increased when used in combination with Testosterone cypionate.Approved
Testosterone enanthateThe therapeutic efficacy of Ferulic acid can be increased when used in combination with Testosterone enanthate.Approved
Testosterone undecanoateThe therapeutic efficacy of Ferulic acid can be increased when used in combination with Testosterone undecanoate.Approved, Investigational
TetrahydropalmatineFerulic acid may increase the hypotensive activities of Tetrahydropalmatine.Investigational
TheodrenalineFerulic acid may increase the hypotensive activities of Theodrenaline.Investigational
Tiaprofenic acidTiaprofenic acid may increase the anticoagulant activities of Ferulic acid.Approved
TiboloneTibolone may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
TicagrelorTicagrelor may increase the anticoagulant activities of Ferulic acid.Approved
TiclopidineTiclopidine may increase the anticoagulant activities of Ferulic acid.Approved
TicrynafenTicrynafen may increase the hypotensive activities of Ferulic acid.Withdrawn
Tiludronic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololTimolol may increase the hypotensive activities of Ferulic acid.Approved
TinoridineTinoridine may increase the anticoagulant activities of Ferulic acid.Investigational
TinzaparinTinzaparin may increase the anticoagulant activities of Ferulic acid.Approved
TioclomarolTioclomarol may increase the anticoagulant activities of Ferulic acid.Experimental
TipranavirTipranavir may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
TirofibanTirofiban may increase the anticoagulant activities of Ferulic acid.Approved
TixocortolThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Tixocortol.Approved, Withdrawn
TobramycinFerulic acid may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TolazolineTolazoline may increase the hypotensive activities of Ferulic acid.Approved, Vet Approved
Tolfenamic AcidTolfenamic Acid may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
TolmetinTolmetin may increase the anticoagulant activities of Ferulic acid.Approved
TolonidineFerulic acid may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Ferulic acid.Approved
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Ferulic acid.Approved
TositumomabThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Tositumomab.Approved, Investigational
TrandolaprilTrandolapril may increase the hypotensive activities of Ferulic acid.Approved
TranilastTranilast may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
TranylcypromineTranylcypromine may increase the hypotensive activities of Ferulic acid.Approved, Investigational
TrapidilTrapidil may increase the anticoagulant activities of Ferulic acid.Approved
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Ferulic acid.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Ferulic acid.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Triamcinolone.Approved, Vet Approved
TriamtereneFerulic acid may decrease the antihypertensive activities of Triamterene.Approved
TribenosideTribenoside may increase the anticoagulant activities of Ferulic acid.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Ferulic acid.Approved, Vet Approved
TriflusalTriflusal may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
TrimazosinTrimazosin may increase the hypotensive activities of Ferulic acid.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Ferulic acid.Approved, Investigational
TriptolideTriptolide may increase the anticoagulant activities of Ferulic acid.Investigational
Trolamine salicylateTrolamine salicylate may increase the anticoagulant activities of Ferulic acid.Approved
TrovafloxacinFerulic acid may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinFerulic acid may increase the anticoagulant activities of Troxerutin.Investigational
UdenafilUdenafil may increase the antihypertensive activities of Ferulic acid.Approved, Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Ferulic acid.Approved, Investigational
UrapidilUrapidil may increase the hypotensive activities of Ferulic acid.Investigational
UrokinaseUrokinase may increase the anticoagulant activities of Ferulic acid.Approved, Investigational, Withdrawn
ValdecoxibThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValrubicinFerulic acid may decrease the excretion rate of Valrubicin which could result in a higher serum level.Approved
ValsartanValsartan may increase the hypotensive activities of Ferulic acid.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Ferulic acid.Approved
VardenafilVardenafil may increase the antihypertensive activities of Ferulic acid.Approved
VincamineFerulic acid may increase the hypotensive activities of Vincamine.Experimental
VinpocetineFerulic acid may increase the hypotensive activities of Vinpocetine.Investigational
Vitamin EVitamin E may increase the anticoagulant activities of Ferulic acid.Approved, Nutraceutical, Vet Approved
VorapaxarThe risk or severity of adverse effects can be increased when Vorapaxar is combined with Ferulic acid.Approved
WarfarinFerulic acid may increase the anticoagulant activities of Warfarin.Approved
XimelagatranFerulic acid may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
XipamideFerulic acid may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the hypotensive activities of Ferulic acid.Approved, Investigational
YohimbineYohimbine may decrease the antihypertensive activities of Ferulic acid.Approved, Investigational, Vet Approved
ZaltoprofenZaltoprofen may increase the anticoagulant activities of Ferulic acid.Approved, Investigational
ZeranolZeranol may decrease the anticoagulant activities of Ferulic acid.Vet Approved
ZileutonZileuton may increase the anticoagulant activities of Ferulic acid.Approved, Investigational, Withdrawn
ZofenoprilFerulic acid may increase the hypotensive activities of Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Ferulic acid is combined with Zoledronic acid.Approved
ZomepiracZomepirac may increase the anticoagulant activities of Ferulic acid.Withdrawn
Zoptarelin doxorubicinFerulic acid may decrease the excretion rate of Zoptarelin doxorubicin which could result in a higher serum level.Investigational
ZorubicinFerulic acid may decrease the excretion rate of Zorubicin which could result in a higher serum level.Experimental
Food Interactions
Not Available

References

General References
Not Available
External Links
Human Metabolome Database
HMDB0000954
KEGG Compound
C01494
PubChem Compound
445858
PubChem Substance
99444238
ChemSpider
393368
BindingDB
50214744
ChEBI
17620
ChEMBL
CHEMBL32749
HET
FER
Wikipedia
Ferulic_acid
PDB Entries
1gkl / 1gw2 / 1gwt / 1jt2 / 1kyz / 1uwc / 2bjh / 2bnj / 2wtn / 3cbg
show 9 more

Clinical Trials

Clinical Trials
Not Available

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.906 mg/mLALOGPS
logP1.58ALOGPS
logP1.67ChemAxon
logS-2.3ALOGPS
pKa (Strongest Acidic)3.77ChemAxon
pKa (Strongest Basic)-4.9ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area66.76 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity51.5 m3·mol-1ChemAxon
Polarizability19.18 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9614
Blood Brain Barrier-0.5305
Caco-2 permeable+0.7183
P-glycoprotein substrateNon-substrate0.5662
P-glycoprotein inhibitor INon-inhibitor0.9018
P-glycoprotein inhibitor IINon-inhibitor0.8895
Renal organic cation transporterNon-inhibitor0.9086
CYP450 2C9 substrateNon-substrate0.7464
CYP450 2D6 substrateNon-substrate0.8922
CYP450 3A4 substrateNon-substrate0.6289
CYP450 1A2 substrateNon-inhibitor0.7513
CYP450 2C9 inhibitorNon-inhibitor0.5793
CYP450 2D6 inhibitorNon-inhibitor0.9588
CYP450 2C19 inhibitorNon-inhibitor0.6276
CYP450 3A4 inhibitorNon-inhibitor0.924
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.7745
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9076
BiodegradationReady biodegradable0.7554
Rat acute toxicity1.4314 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9754
hERG inhibition (predictor II)Non-inhibitor0.9575
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (2 TMS)GC-MSsplash10-05g4-1978000000-1097d5b300514a0489df
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (2 TMS)GC-MSsplash10-00kv-2964000000-3d20d62c97c33247cfcf
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-00ku-1965000000-ebee2a916fe97f0270a1
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (2 TMS)GC-MSsplash10-00di-9654000000-b3f1759076cffd2ac235
GC-MS Spectrum - GC-MS (2 TMS)GC-MSsplash10-000m-3975000000-5a41c311d78f7219474c
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0006-1900000000-5dffac87fe7c815de4ce
GC-MS Spectrum - EI-BGC-MSsplash10-0006-2900000000-8db541bacfe47b9e0c8b
GC-MS Spectrum - EI-BGC-MSsplash10-0006-2900000000-a338415bd30d4e62e664
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-05g4-1978000000-1097d5b300514a0489df
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00kv-2964000000-3d20d62c97c33247cfcf
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00ku-1965000000-ebee2a916fe97f0270a1
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00di-9654000000-b3f1759076cffd2ac235
GC-MS Spectrum - GC-MSGC-MSsplash10-000m-3975000000-5a41c311d78f7219474c
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-00kv-1954000000-9dae07505bd18466be87
Mass Spectrum (Electron Ionization)MSsplash10-0006-5900000000-8c81de6c352294475072
MS/MS Spectrum - Quattro_QQQ 10V, Positive (Annotated)LC-MS/MSsplash10-004i-0900000000-d193da7a6efffdab2dbb
MS/MS Spectrum - Quattro_QQQ 25V, Positive (Annotated)LC-MS/MSsplash10-00kr-7900000000-b5b8d28b28c8067c3932
MS/MS Spectrum - Quattro_QQQ 40V, Positive (Annotated)LC-MS/MSsplash10-002r-9000000000-d3616a5367a7a2a9b3c6
MS/MS Spectrum - EI-B (HITACHI M-52) , PositiveLC-MS/MSsplash10-0006-1900000000-5dffac87fe7c815de4ce
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-0006-0900000000-c173873ef0d975be6c34
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-001i-0900000000-0b9174ecaba08b2f01b9
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-001i-1900000000-eff77e27aef254928643
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-001r-9700000000-18946fad05ffb1f78a7d
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-001r-9300000000-e2221a73d3d078bf6e03
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , PositiveLC-MS/MSsplash10-0002-0900000000-653c9a454414dd8b8b50
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) 30V, PositiveLC-MS/MSsplash10-002b-0900000000-62b2ee8bf9571be3d97f
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , NegativeLC-MS/MSsplash10-001i-0900000000-a7cded21e6010eb8bce2
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0006-0900000000-c173873ef0d975be6c34
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-0900000000-0b9174ecaba08b2f01b9
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001i-1900000000-eff77e27aef254928643
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001r-9700000000-18946fad05ffb1f78a7d
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-001r-9300000000-e2221a73d3d078bf6e03
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-001i-0900000000-a7cded21e6010eb8bce2
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-002b-0900000000-cdced9ddbcdaedf2f1b9
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-002b-0900000000-df06f7f58486ac25c21b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-653c9a454414dd8b8b50
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-002b-0900000000-62b2ee8bf9571be3d97f
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-000j-0900000000-1ef88466d8544694f557
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-000j-0900000000-bb82c87030f6232d5663
MS/MS Spectrum - , positiveLC-MS/MSsplash10-002b-2921111101-6d1aa599f0f132a3695d
1H NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
13C NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as hydroxycinnamic acids. These are compounds containing an cinnamic acid where the benzene ring is hydroxylated.
Kingdom
Organic compounds
Super Class
Phenylpropanoids and polyketides
Class
Cinnamic acids and derivatives
Sub Class
Hydroxycinnamic acids and derivatives
Direct Parent
Hydroxycinnamic acids
Alternative Parents
Coumaric acids and derivatives / Cinnamic acids / Methoxyphenols / Styrenes / Phenoxy compounds / Methoxybenzenes / Anisoles / Alkyl aryl ethers / 1-hydroxy-2-unsubstituted benzenoids / Monocarboxylic acids and derivatives
show 4 more
Substituents
Cinnamic acid / Coumaric acid or derivatives / Hydroxycinnamic acid / Methoxyphenol / Phenoxy compound / Anisole / Methoxybenzene / Styrene / Phenol ether / 1-hydroxy-2-unsubstituted benzenoid
show 14 more
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
ferulic acids (CHEBI:17620) / Coniferyl alcohol derivatives (C01494)

Targets

Kind
Protein
Organism
Clostridium thermocellum
Pharmacological action
Unknown
General Function
Endo-1,4-beta-xylanase activity
Specific Function
Not Available
Gene Name
xynY
Uniprot ID
P51584
Uniprot Name
Endo-1,4-beta-xylanase Y
Molecular Weight
119671.86 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Clostridium thermocellum (strain ATCC 27405 / DSM 1237)
Pharmacological action
Unknown
General Function
Xylan endo-1,3-beta-xylosidase activity
Specific Function
Not Available
Gene Name
xynZ
Uniprot ID
P10478
Uniprot Name
Endo-1,4-beta-xylanase Z
Molecular Weight
92262.3 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Butyrivibrio proteoclasticus
Pharmacological action
Unknown
General Function
Not Available
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
D2YW37
Uniprot Name
Est1e
Molecular Weight
28020.97 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Synechocystis sp. (strain PCC 6803 / Kazusa)
Pharmacological action
Unknown
General Function
O-methyltransferase activity
Specific Function
Not Available
Gene Name
Not Available
Uniprot ID
Q55813
Uniprot Name
O-methyltransferase
Molecular Weight
24312.805 Da
References
  1. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]

Drug created on September 15, 2010 15:25 / Updated on March 02, 2018 03:27